

Chronic Systemic Co-infections

leaf extract (many sources), NSC-100, and Laktoferrin. These products have been used to boost immune systems. Although they appear to help many patients, their clinical effectiveness in chronic-illness patients has not been carefully evaluated. They appear to be useful during therapy to boost the immune system or after antibiotic therapy in a maintenance program to prevent relapse and opportunistic secondary infections.

Lipid Replacement Therapy for Chronic Infections and Restoring Mitochondrial Function

Lipid Replacement Therapy is useful in providing membrane lipids in unoxidized forms to repair nerve and mitochondrial membranes that are damaged by heavy metals, chemicals, and infections.²⁰ For LD patients, we recommend the oral supplement Healthy Aging containing NTFactor (Nutritional Therapeutics). This product comes as tablets that are taken twice per day. For children, it should be ground up between two spoons into a coarse powder that can be added to several spoonfuls of applesauce. The NTFactor is not bitter, but it is slightly sour, and some children actually like the taste. The


dose should be four to six tablets twice per day for adults. For children: one-half to one tablet for children up to two years-old; two tablets for children two to three years old; three to four tablets for children four to five years old; and four to five tablets for children five years old and older. Research has demonstrated no adverse responses with NTFactor, even at many times these doses. Since this formulation is a completely natural membrane lipid mixture, there are no known toxicities and no known toxic dose limits. NTFactor can also be taken in a form with vitamins, minerals, and probiotics (Propax). Lipid Replacement Therapy has been shown to improve fatigue scores and mitochondrial function in various chronic illnesses.²⁰

Prof. Garth L. Nicolson
Department of Molecular Pathology
The Institute for Molecular Medicine
16371 Gothard St.
Huntington Beach, California 92647
714-596-6636, Fax: 714-596-3791
gnicolson@immed.org
www.immed.org

*The author has no financial interest in any products discussed in this contribution.

Professor Garth L. Nicolson is the President, Chief Scientific Officer and Research Professor at the Institute for Molecular Medicine in Huntington Beach, California. Born in 1943 in Los Angeles, Dr. Nicolson received his BS in Chemistry from University of California at Los Angeles in 1965 and his PhD in Biochemistry and Cell Biology from the University of California at San Diego in 1970. He is currently Professor of Integrative Medicine at Capitol University of Integrative Medicine and a Conjoint Professor at the University of Newcastle (Australia). He was formally the David Bruton Jr. Chair in Cancer Research and Professor and Chairman of the Department of Tumor Biology at the University of Texas M. D. Anderson Cancer Center in Houston, and he was Professor of Internal Medicine and Professor of Pathology and Laboratory Medicine at the University of Texas Medical School at Houston. He was also Professor of Comparative Pathology at Texas A & M University. Professor Nicolson has published over 580 medical and scientific papers (including three *Current Contents*

Citation Classics), edited 14 books and served on the Editorial Boards of 20 medical and scientific journals. Professor Nicolson has won many awards, such as the Burroughs Wellcome Medal of the Royal Society of Medicine (United Kingdom), Stephen Paget Award of the Metastasis Research Society, the US National Cancer Institute Outstanding Investigator Award, and the Innovative Medicine Award of Canada. He is also a Colonel (Honorary) of the US Army Special Forces and a US Navy SEAL (Honorary) for his work on Armed Forces and veterans' illnesses.



Notes

1. Burgdorfer WA, Barbour AG, Hayes SF, et al. Lyme disease – a tick-borne spirochetosis? *Science*. 1982; 216:1317-1319.
2. Kind A, Schneid E, Anderson F, et al. Lyme disease guidelines for Minnesota clinicians: Epidemiology, microbiology, diagnosis, treatment and prevention. Minnesota Department of Public Health, 1999. Available at: <http://www.state.mn.us/divs/dpc/adps/lyme/guideline>.
3. Gale A, Ringdahl E. Tick-borne diseases. *Amer Fam Physician*. 2001; 64:461-466. Available at: <http://www.aafp.org/afp/200110801/461>.
4. Burrascano JJ, Jr. Advanced topics in Lyme disease. Diagnostic hints and treatment guidelines for Lyme and other tick borne illnesses. LymeNet On-Line Library, Burrascano Treatment Guidelines, 2000. Available at: <http://www2.lymenet.org/domino/file.nsf/UID/guidelines>.
5. Nicolson GL, Nasralla M, Franco AR, et al. Diagnosis and integrative treatment of intracellular bacterial infections in chronic fatigue and fibromyalgia syndromes, Gulf War illness, rheumatoid arthritis and other chronic illnesses. *Clin Pract Alt Med*. 2000; 1(2):92-102. Available at: http://www.immed.org/illness/infectious_disease_research.
6. Nicolson GL, Nasralla M, Franco AR, et al. Mycoplasma infections in fatigue illnesses: Chronic fatigue and fibromyalgia syndromes, Gulf War illness and rheumatoid arthritis. *J Chronic Fatigue Syndr*. 2000; 6(3):23-39. Available at: http://www.immed.org/illness/infectious_disease_research.
7. Verdon ME, Sigal LH. Recognition and management of Lyme disease. *Amer Fam Physician*. 1997; 56:427-436. Available at: <http://www.aafp.org/afp/970800ap/lymedis>.
8. Klemptner MS, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. *Amer J Med*. 2001; 110:217-219.
9. Mylonakis E. When to suspect and how to monitor babesiosis. *Amer Family Physicia*. 2001; 63:1969-1974. Available at: <http://www.aafp.org/afp/20010515/1969>.
10. Eskow E, Adelson ME, Rao RV, Mordechai E. Evidence for disseminated mycoplasma fermentans in New Jersey residents with antecedent tick attachment and subsequent musculoskeletal symptoms. *J Clin Rheumatol*. 2003; 9:77-87.
11. Nicolson GL, Gan R, Haier J. Multiple co-infections (mycoplasma, chlamydia, human herpesvirus-6) in blood of chronic fatigue syndrome patients: Association with signs and symptoms. *Acta Pathol Microbiol Immunol Scand*. 2003; 111: 557-566.
12. Nicolson GL, Berns P, Nasralla M, Haier J, Pomfret J. High frequency of systemic mycoplasma infections in Gulf War veterans and civilians with Amyotrophic Lateral Sclerosis (ALS). *J Clin Neurosci*. 2002; 9:525-529.
13. Eppes SC. Lyme disease: Current therapies and prevention. *Infect Med*. 2001; 18:388-395. Available at: <http://www.medscape.com/SPC/IIM/2001/v18.n08/m1808.01eppe/mig-pnt-m1808.01.eppe>.
14. Dattwyler RJ, Volkman DJ, Conaty SM, et al. Amoxicillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. *Lancet*. 1990; 336:1404-1406.
15. Luger SW, Papparoni P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. *Antimicrob Agents Chemother*. 1995; 39:661-667.
16. Nicolson GL. Considerations when undergoing treatment for chronic infections found in chronic fatigue syndrome, fibromyalgia syndrome and Gulf War illnesses. (Part 1). Antibiotics Recommended when indicated for treatment of Gulf War illness/CFIDS/FMS (Part 2). *Intern J Med*. 1998; 1:115-117, 123-128. Available at: <http://www.immed.org/>.
17. Nicolson GL, Nasralla M, Franco AR, et al. Diagnosis and integrative treatment of intracellular bacterial infections in chronic fatigue and fibromyalgia syndromes, Gulf War illness, rheumatoid arthritis and other chronic illnesses. *Clin Pract Alt Med*. 2000; 1:92-102.
18. Nicolson GL, Ngwenya R. Dietary considerations for patients with chronic illnesses and multiple chronic infections. A brief outline of eighteen dietary steps to better health. *Townsend Lett*. 2001; 219:62-65. Available at: http://www.immed.org/illness/treatment_considerations.
19. Horowitz R. Lyme Disease and other tick-borne diseases. ILADS Annual Conference, October 29-30, 2005.
20. Nicolson GL, Ellithorpe R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. *J Chronic Fatigue Syndr*. 2006; 13(1):57-68.